Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives

International Journal of Cardiology

Volumn 185, Issue , 2015, Pages 9-18

  Moschonas, I C ^a   Goudevenos, J A ^b   Tselepis, A D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Myocardial infarction; Peripheral artery disease; Protease activated receptor 1; Stent thrombosis; Stroke; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CLOPIDOGREL; HEPARIN; HIRULOG; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBIN RECEPTOR ANTAGONIST; TICAGRELOR; VORAPAXAR; IMINE; LACTONE; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS SURGERY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PLASMA HALF LIFE; PRIORITY JOURNAL; QT PROLONGATION; SECONDARY PREVENTION; SINGLE DRUG DOSE; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DRUG COMBINATION; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; STENT; STROKE;

CLINICAL TRIALS AS TOPIC; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; IMINES; LACTONES; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; STENTS; STROKE; THROMBOSIS;

EID: 84928236170     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.049     Document Type: Review

References (86)

1. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: World Health Organization Available from: http://www.who.int/cardiovascular-diseases/publications/atlas-cvd/en/ 2011
2. Brito F. De Souza, and P. Tricoci Novel antiplatelet agents: focus on thrombin receptor antagonists J. Cardiovasc. Transl. Res. 6 2013 415 424
3. H. Lee, and J.R. Hamilton Physiology, pharmacology, and therapeutic potential of protease-activated receptors in cardiovascular disease Pharmacol. Ther. 134 2012 246 259
4. T.K. Vu, D.T. Hung, V.I. Wheaton, and S.R. Coughlin Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 64 1991 1057 1068
5. S. Nystedt, K. Emilsson, C. Wahlestedt, and J. Sundelin Molecular cloning of a potential proteinase activated receptor Proc. Natl. Acad. Sci. U. S. A. 91 1994 9208 9212
6. H. Ishihara, A.J. Connolly, and D. Zeng Protease-activated receptor 3 is a second thrombin receptor in humans Nature 386 1997 502 506
7. W.F. Xu, H. Andersen, and T.E. Whitmore Cloning and characterization of human protease-activated receptor 4 Proc. Natl. Acad. Sci. U. S. A. 95 1998 6642 6666
8. M.L. Kahn, Y.W. Zheng, and W. Huang A dual thrombin receptor system for platelet activation Nature 394 1998 690 694
9. M.G. Davey, and E.F. Lüscher Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets Nature 216 1967 857 858
10. V. Ramakrishnan, F. DeGuzman, M. Bao, S.W. Hall, L.L. Leung, and D.R. Phillips A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V Proc. Natl. Acad. Sci. U. S. A. 98 2001 1823 1828
11. E. De Candia, S.W. Hall, S. Rutella, R. Landolfi, R.K. Andrews, and R. De Cristofaro Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets J. Biol. Chem. 276 2001 4692 4698
12. S.L. Jacques, and A. Kuliopulos Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage Biochem. J. 376 2003 733 740
13. L. Covic, A.L. Gresser, and A. Kuliopulos Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets Biochemistry 39 2000 5458 5467
14. L. Covic, C. Singh, H. Smith, and A. Kuliopulos Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome Thromb. Haemost. 87 2002 722 727
15. A.J. Leger, S.L. Jacques, and J. Badar Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis Circulation 113 2006 1244 1254
16. A. Arachiche, M.M. Mumaw, M. de la Fuente, and M.T. Nieman Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin J. Biol. Chem. 288 2013 32553 32562
17. W.F. Bahou, B.S. Coller, C.L. Potter, K.J. Norton, J.L. Kutok, and M.S. Goligorsky The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation J. Clin. Invest. 91 1993 1405 1413
18. S. Seeley, L. Covic, S.L. Jacques, J. Sudmeier, J.D. Baleja, and A. Kuliopulos Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding Chem. Biol. 10 2003 1033 1041
19. R.E. Gerszten, J. Chen, and M. Ishii Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface Nature 368 1994 648 651
20. T. Nanevicz, M. Ishii, and L. Wang Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site J. Biol. Chem. 270 1995 21619 21625
21. D.J. Lerner, M. Chen, T. Tram, and S.R. Coughlin Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function J. Biol. Chem. 271 1996 13943 13947
22. B.D. Blackhart, L. Ruslim-Litrus, and C.-C. Lu Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide Mol. Pharmacol. 58 2000 1178 1187
23. 12/13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets J. Cell Biol. 144 1999 745 754
24. E. Hirsch, O. Bosco, and P. Tropel Resistance to thromboembolism in PI3Kgamma-deficient mice FASEB J. 15 2001 2019 2021
25. D.T. Hung, Y.H. Wong, T.K. Vu, and S.R. Coughlin The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase J. Biol. Chem. 267 1992 20831 20834
26. R.R. Vassallo Jr., T. Kieber-Emmons, K. Cichowski, and L.F. Brass Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides J. Biol. Chem. 267 1992 6081 6085
27. A.N. Giesberts, G. van Willigen, E.G. Lapetina, and J.W. Akkerman Regulation of platelet glycoprotein IIb/IIIa (integrin α IIB β 3) function via the thrombin receptor Biochem. J. 309 1995 613 620
28. T.R. Faruqi, E.J. Weiss, M.J. Shapiro, W. Huang, and S.R. Coughlin Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function J. Biol. Chem. 275 2000 19728 19734
29. B. Voss, J.N. McLaughlin, M. Holinstat, R. Zent, and H.E. Hamm PAR-1, but not PAR-4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis Mol. Pharmacol. 71 2007 1399 1406
30. S. Kim, C. Foster, and A. Lecchi Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling Blood 99 2002 3629 3636
31. K. Ishii, J. Chen, and M. Ishii Inhibition of thrombin receptor signaling by a G protein-coupled receptor kinase. Functional specificity among G protein-coupled receptor kinases J. Biol. Chem. 269 1994 1125 1130
32. C. Tiruppathi, W. Yan, and R. Sandoval G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells Proc. Natl. Acad. Sci. U. S. A. 97 2000 7440 7445
33. M.M. Paing, A.B. Stutts, T.A. Kohout, R.J. Lefkowitz, and J. Trejo β-arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation J. Biol. Chem. 277 2002 1292 1300
34. C.H. Chen, M.M. Paing, and J. Trejo Termination of protease-activated receptor-1 signaling by β-arrestins is independent of receptor phosphorylation J. Biol. Chem. 279 2004 10020 10031
35. H.D. White Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions Am. Heart J. 161 2011 450 461
36. V.L. Serebruany, M. Kogushi, D. Dastros-Pitei, M. Flather, and D.L. Bhatt The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb. Haemost. 102 2009 111 119
37. S. Goto, H. Ogawa, M. Takeuchi, M.D. Flather, and D.L. Bhatt J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur. Heart J. 31 2010 2601 2613
38. M. O' Donoghue LANCELOT ACS: a prospective, randomized, double-blind, placebo-controlled trial of a reversible PAR-1 thrombin receptor antagonist in patients with acute coronary syndromes Presented at the 2010 TCT Congress. September 21-25, 2010. Washington, DC 2010
39. D. Doller, S. Chackalamannil, M. Czarniecki, R. McQuade, and V. Ruperto Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists Bioorg. Med. Chem. Lett. 9 1999 901 906
40. K.I. Kalantzi, M.E. Tsoumani, I.A. Goudevenos, and A.D. Tselepis Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives Expert. Rev. Clin. Pharmacol. 5 2012 319 336
41. S. Chackalamannil, Y. Wang, and W.J. Greenlee Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J. Med. Chem. 51 2008 3061 3064
42. J.R. Cho, F. Rollini, F. Franchi, E. Ferrante, and D.J. Angiolillo Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar Vasc. Health Risk Manag. 10 2014 177 188
43. C. Zhang, Y. Srinivasan, and D.H. Arlow High-resolution crystal structure of human protease-activated receptor 1 bound to the antagonist vorapaxar Nature 492 2012 387 392
44. A. Ghosal, X. Lu, and N. Penner Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist Drug Metab. Dispos. 39 2011 30 38
45. M. Ueno, J.L. Ferreiro, and D.J. Angiolillo Mechanism of action and clinical development of platelet thrombin receptor antagonists Expert. Rev. Cardiovasc. Ther. 8 2010 1191 1200
46. T. Kosoglou, P. Statkevich, and B. Kumar The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar J. Clin. Pharmacol. 53 2013 540 549
47. T. Kosoglou, Y. Zhu, and F. Xuan Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin Eur. J. Clin. Pharmacol. 68 2012 1509 1516
48. Y. Xia, S. Chackalamannil, and W.J. Greenlee Discovery of a vorapaxar analog with increased aqueous solubility Bioorg. Med. Chem. Lett. 20 2010 6676 6679
49. M.V. Chelliah, S. Chackalamannil, and Y. Xia Discovery of nor-seco himbacine analogs as thrombin receptor antagonists Bioorg. Med. Chem. Lett. 22 2012 2544 2549
50. T. Kosoglou, L. Reyderman, and R. Tiessen Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects Eur. J. Clin. Pharmacol. 68 2012 249 258
51. T. Kosoglou, L. Reyderman, and C. Kasserra No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects Eur. J. Clin. Pharmacol. 68 2012 291 300
52. X. Chen, T. Kosoglou, and P. Statkevich Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects Int. J. Clin. Pharmacol. Ther. 52 2014 889 899
53. R.F. Storey, J. Kotha, and S.S. Smyth Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER pharmacodynamic substudy Thromb. Haemost. 111 2014 883 891
54. T. Kosoglou, W.K. Kraft, and B. Kumar Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease Eur. J. Clin. Pharmacol. 68 2012 1049 1056
55. P. Statkevich, T. Kosoglou, and R.A. Preston Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment Eur. J. Clin. Pharmacol. 68 2012 1501 1508
56. R.C. Becker, D.J. Moliterno, and L.K. Jennings Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
57. S. Goto, T. Yamaguchi, Y. Ikeda, K. Kato, H. Yamaguchi, and P. Jensen Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome J. Atheroscler. Thromb. 17 2010 156 164
58. P. Tricoci, Z. Huang, and C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. Engl. J. Med. 366 2012 20 33
59. H. White, K. Thygesen, J.S. Alpert, and A. Jaffe Universal MI definition update for cardiovascular disease Curr. Cardiol. Rep. 16 2014 492
60. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 361 2009 1045 1057
61. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
62. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N. Engl. J. Med. 345 2001 494 502
63. Errata in N. Engl. J. Med. 345 1506 2001 1716
64. R.P. Giugliano, L.K. Newby, and R.A. Harrington The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - study design and rational Am. Heart J. 149 2005 994 1002
65. G.W. Stone, M.E. Bertrand, and J.W. Moses Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial JAMA 297 2007 591 602
66. M. Chintala, J. Strony, B. Yang, S. Kurowski, and Q. Li SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys Arterioscler. Thromb. Vasc. Biol. 30 2010 2143 2149
67. Y. Shinohara, S. Goto, M. Doi, and P. Jensen Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke J. Stroke Cerebrovasc. Dis. 21 2012 318 324
68. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting. A randomized multicenter trial Circulation 125 2012 2015 2026
69. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N. Engl. J. Med. 362 2010 1374 1382
70. L. Mauri, D.J. Kereiakes, and R.W. Yeh Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N. Engl. J. Med. 371 2014 2155 2166
71. D.A. Morrow, E. Braunwald, and M.P. Bonaca Vorapaxar in the secondary prevention of atherothrombotic events N. Engl. J. Med. 366 2012 1404 1413
72. D.A. Morrow, B.M. Scirica, and K.A. Fox Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial Am. Heart J. 158 2009 335 341 (e3)
73. D.A. Morrow, M.J. Alberts, and J.P. Mohr Efficacy and safety of vorapaxar in patients with prior ischemic stroke Stroke 44 2013 691 698
74. S. Leonardi, P. Tricoci, and H.D. White Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA-CER) trial Eur. Heart J. 34 2013 1723 1731
75. B.M. Scirica, M.P. Bonaca, and E. Braunwald Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial Lancet 380 2012 1317 1324
76. B.M. Scirica, M.P. Bonaca, and J. Morais Vorapaxar in patients with diabetes and prior MI: findings from the TRA 2P-TIMI 50 trial Circulation 128 2013 A10398
77. M. Valgimigli, P. Tricoci, and Z. Huang Vorapaxar, a platelet thrombin-receptor antagonist, in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from the TRACER trial Circulation 126 2012 A18805
78. M. Valgimigli, P. Tricoci, and Z. Huang Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial) Am. J. Cardiol. 114 2014 665 673
79. C.M. Gibson, P. Tricoci, and C. Abueg Lack of concordance between angiographic core laboratory and CEC in the assessment of stent thrombosis: results from the TRACER angiographic substudy Eur. Heart J. 34 Suppl. 1 2013 240
80. M.P. Bonaca, B.M. Scirica, and E. Braunwald Coronary stent thrombosis with vorapaxar versus placebo. Results from the TRA 2P-TIMI 50 trial J. Am. Coll. Cardiol. 64 2014 2309 2317
81. M.P. Bonaca, B.M. Scirica, and M.A. Creager Vorapaxar in patients with peripheral artery disease: results from TRA 2P-TIMI 50 Circulation 127 2013 1522 1529
82. D.J. Whellan, P. Tricoci, and E. Chen Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery. Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) J. Am. Coll. Cardiol. 63 2014 1048 1057
83. M.P. Bonaca, B.M. Scirica, and E. Braunwald New ischemic stroke and outcomes with vorapaxar versus placebo. Results from the TRA 2P-TIMI 50 trial J. Am. Coll. Cardiol. 64 2014 2318 2326
84. K.W. Mahaffey, Z. Huang, and L. Wallentin Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER trial) Am. J. Cardiol. 113 2014 936 944
85. B.M. Scirica, M.P. Bonaca, and E. Braunwald Vorapaxar for secondary prevention after myocardial infarction according to aspirin dose-insights from the TRA 2P-TIMI 50 trial Circulation 126 2012 A14508
86. P. Tricoci, Z. Huang, and van de Werf Vorapaxar with and without thienopyridine use in acute coronary syndromes: results from the TRACER trial Eur. Heart J. 33 2012 495 496